HARVARD BIOSCIENCE INC
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(Unaudited, in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at March 31, 2024 | 43,421 | $434 | $233,451 | $(150,299) | $(14,774) | $68,812 |
| Stock option exercises | 4 | - | 13 | - | - | 13 |
| Stock purchase plan | 72 | 1 | 175 | - | - | 176 |
| Vesting of restricted stock units | 116 | 1 | - | - | - | 1 |
| Shares withheld for taxes | (2) | - | (12) | - | - | (12) |
| Stock-based compensation expense | - | - | 1,278 | - | - | 1,278 |
| Net loss | - | - | - | (2,927) | - | (2,927) |
| Other comprehensive loss | - | - | - | - | (94) | (94) |
| Balance at June 30, 2024 | 43,611 | $436 | $234,905 | $(153,226) | $(14,868) | $67,247 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at March 31, 2023 | 42,190 | $455 | $230,108 | $(141,568) | $(14,655) | $74,340 |
| Stock option exercises | 173 | 2 | 403 | - | - | 405 |
| Stock purchase plan | 91 | - | 215 | - | - | 215 |
| Vesting of restricted stock units | 287 | - | - | - | - | - |
| Shares withheld for taxes | (54) | - | (295) | - | - | (295) |
| Stock-based compensation expense | - | - | 1,102 | - | - | 1,102 |
| Net loss | - | - | - | (980) | - | (980) |
| Other comprehensive income | - | - | - | - | 601 | 601 |
| Balance at June 30, 2023 | 42,687 | $457 | $231,533 | $(142,548) | $(14,054) | $75,388 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2023 | 43,395 | $434 | $232,435 | $(145,605) | $(14,190) | $73,074 |
| Stock option exercises | 8 | - | 28 | - | - | 28 |
| Stock purchase plan | 72 | 1 | 175 | - | - | 176 |
| Vesting of restricted stock units | 150 | 1 | - | - | - | 1 |
| Shares withheld for taxes | (14) | - | (59) | - | - | (59) |
| Stock-based compensation expense | - | - | 2,326 | - | - | 2,326 |
| Net loss | - | - | - | (7,621) | - | (7,621) |
| Other comprehensive loss | - | - | - | - | (678) | (678) |
| Balance at June 30, 2024 | 43,611 | $436 | $234,905 | $(153,226) | $(14,868) | $67,247 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2022 | 42,082 | $454 | $229,008 | $(142,190) | $(15,052) | $72,220 |
| Stock option exercises | 212 | 3 | 506 | - | - | 509 |
| Stock purchase plan | 91 | - | 215 | - | - | 215 |
| Vesting of restricted stock units | 412 | - | - | - | - | - |
| Shares withheld for taxes | (110) | - | (451) | - | - | (451) |
| Stock-based compensation expense | - | - | 2,255 | - | - | 2,255 |
| Net loss | - | - | - | (358) | - | (358) |
| Other comprehensive income | - | - | - | - | 998 | 998 |
| Balance at June 30, 2023 | 42,687 | $457 | $231,533 | $(142,548) | $(14,054) | $75,388 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.